Yolk Sac Tumor

Observed

→ investigated in trials for

Etoposidesmall_molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ifosfamidesmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall_molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bleomycin

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Pineal Region Yolk Sac Tumor

Yolk Sac Tumor studied in …STUDIED_INderived10 of 24show all (up to 200)
→ studied in	NCT04684368Phase 2 · recruiting A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Pineal Region Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04715191Phase 1 · recruiting Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02375204Phase 3 · active not recruiting Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06638931Phase 2 · recruiting Agnostic Therapy in Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05103631Phase 1 · active not recruiting Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07148050Phase 1 · recruiting Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04377932Phase 1 · active not recruiting Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07224568Phase 1 · not yet recruiting Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06198296Phase 1 · recruiting Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05564026recruiting Molecular Epidemiology of Pediatric Germ Cell Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)	—	—	Yolk Sac Tumor	1	Observed	clinicaltrials	graph →

Yolk Sac Tumor studied in …STUDIED_INderived10 of 24show all (up to 200)

→ studied in

NCT04684368Phase 2 · recruiting

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT04715191Phase 1 · recruiting

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT02375204Phase 3 · active not recruiting

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT06638931Phase 2 · recruiting

Agnostic Therapy in Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT05103631Phase 1 · active not recruiting

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT07148050Phase 1 · recruiting

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT04377932Phase 1 · active not recruiting

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT07224568Phase 1 · not yet recruiting

Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT06198296Phase 1 · recruiting

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed

→ studied in

NCT05564026recruiting

Molecular Epidemiology of Pediatric Germ Cell Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (10 active)

—

Observed